Introduction
============

Physical activity has emerged as essential interventional therapeutic strategy against cardiovascular disease (CVD) due to its impact on several metabolic systems (e.g. lipid and glucose metabolism [@B1]) and its influence on angiogenesis [@B2], inflammation [@B3] and atherosclerosis/calcification [@B4]. Total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDL-C) and triglycerides (TG) represent the most important targets of the lipid metabolism for lifestyle and/or drug therapy-based treatment of cardiovascular disease.

To date, favourable effects of physical activity and exercise on lipid and lipoprotein profiles have been suggested [@B5]. Apart from quantitative changes of serum lipids, a positive impact of exercise on HDL particle maturation, composition and functionality has been reported [@B6]. In view of the well-established role of dyslipidemia in the pathogenesis of CVD, there has been substantial interest to elucidate lipid and lipoprotein metabolism and mechanisms related to the beneficial effects of exercise on CV health [@B7]. Metabolic adaptations affecting lipid levels and homeostasis, induced by life-style change composed of physical activity, diet and weight control can have substantial impact on the management of CVD.

Despite the long known inverse relationship between HDL-C levels and cardiovascular risk in the general population [@B8], there is accumulating evidence that the quality, rather than the quantity, of HDL plays a central role in CVD risk protection [@B9], [@B10]. In this regard, HDL quality is evolving as a promising diagnostic marker for cardiovascular outcome [@B11] and the protein composition of HDL plays a key role in mediating its cardioprotective functions [@B12]. The HDL proteome is profoundly altered in acute phase or chronic conditions [@B13] and, importantly, is associated with clinical outcomes [@B14]. Specifically, accumulation of serum amyloid A (SAA) or surfactant protein B (SPB) occurs in different patient populations at high cardiovascular risk [@B15], [@B16]. SAA is a major acute-phase protein and its levels rise rapidly during inflammatory processes. Increased incorporation of SAA into HDL was shown to be a marker of on-going systemic inflammation and to be directly associated with dysfunctional HDL properties [@B12]. SPB is crucial to lung function by maintaining surface tension and stability on the alveolar-capillary membranes. SPB flowing into the circulation caused by membrane leakage has been reported to occur in several diseases and plasma SPB has been identified as biomarker in chronic heart failure [@B17], [@B18]. Importantly, we have shown previously that high amounts of HDL-bound SAA and SPB contribute to cardiovascular events and mortality in a high risk population [@B19].

It is well known that physical activity increases HDL-quantity however there is no data available concerning the influence of sports on HDL-quality. Thus, determining the effect of physical activity on SAA and SPB levels as well as the identification of other factors that might have an impact on SAA and SPB was the aim of the present prospective study.

Material and Methods
====================

In total 109 subjects were recruited. Inclusion criteria were: age between 30-65 years and physical ability to perform endurance exercise. Exclusion criteria were: age \<30 or \>65 years, no ability to perform endurance exercise, current oncologic or infectious disease (anamnestic or increased inflammation parameters at baseline). 11 subjects did not complete the study for different reasons (accidents, loss of motivation, etc.). Finally, 98 subjects completed the study. The study population therefore consisted of 38 female and 60 male subjects aged 30-65 years with at least one classic cardiovascular risk factor: overweight (BMI \>25.0 kg/m^2^), hypertension (SBP \> 140 +/- DBP \> 85 mmHg at rest / antihypertensive medication), hyper/dyslipidemia (anamnestic statin therapy), diabetes mellitus (HbA1c \> 6.5 rel% / DM medication), current smoking, known CHD (anamnestic MI, PCI, CABG, stroke) and positive family anamnesis for MI/CVD/stroke of mother and/or father. The anamnestic weekly alcohol intake was measured in units: 1 unit corresponds to 0.33 l beer, 0.125 l red/white wine or 0.02 l spirits.

The study was carried out in adherence to the Declaration of Helsinki and its later amendments as well as to the ethical standards in sports and exercise research [@B20]. The protocol has been approved by the Ethical Commission of the Medical University of Vienna (EC-number: 1830/2013) and informed consent was obtained from all subjects before inclusion.

Measurement of anthropometric data and bicycle stress test (ergometry)
----------------------------------------------------------------------

After detailed anamnesis and physical examination including the measurement of height, weight, body water, body muscle mass and body fat (with a diagnostic scale, Beurer BG 16, Beurer GmbH, Ulm, Germany), subjects had to perform a bicycle stress test (ergometry) at the beginning of the study to define their performance level and to calculate their individual training pulse/target heart rate (using the Karvonen formula with an intensity level of 65-75 % for moderate and 76-93 % for vigorous intensity). Subjects were let to decide the kind of physical activity/sports, however, they were asked to perform at least 75 minutes/week of vigorous or 150 minutes/week of moderate intensity endurance training (or a mixture; strength training was allowed but not mandatory) within the calculated training pulse. A second ergometry was performed at the end of the study (after 8 months) to prove and also quantify exactly and objectively the change/gain in performance. Therefore, we relinquished the leading of a training protocol. Bicycle stress tests were always ECG-monitored and performed with the same system (Ergometer eBike comfort, GE Medical Systems, Freiburg, Germany) starting with 25 watts and increasing every 2 minutes by 25 watts (according to the protocol of the Austrian Society of Cardiology which is equal to the guidelines of the European Society of Cardiology). Blood pressure and heart rate were taken every 2 minutes. Subjects were told to cycle with 50-70 revolutions/min until exhaustion occurred. The target performance was calculated using body surface (calculated according to DuBois formula: body surface (m^2^) = 0.007184 x height \[cm\] ^0.725^ x weight \[kg\] ^0.425^ ) [@B21], sex and age. An individual target performance of 100 % represents the performance of an untrained collective. We estimate that a performance gain of at least 8% is necessary to manifest measurable and clinically relevant changes concerning the lipid profile. Therefore, the study population was divided into 4 groups according to the baseline performance and to the performance gain over the observation period:group 1 consisted of participants with a performance ≤99 % at baseline and a performance gain ≤ 7.9 %;group 2 consisted of participants with a performance ≤99 % at baseline and a performance gain \> 7.9 %;group 3 consisted of participants with a performance \>100 % at baseline and a performance gain ≤ 7.9 %and group 4 consisted of participants with a performance \>100 % at baseline and a performance gain \> 7.9 %.

Routine laboratory analysis
---------------------------

Blood samples were drawn in a not starving state. Blood samples for the determination of SAA and SPB were taken at baseline, after 4 months and after 8 months. All other samples were taken at baseline and every 2 months. All blood samples were taken after 10 minutes of still lying from an arm vein with a tube/adapter system. Samples for determination of routine laboratory parameters were analysed immediately after drawing. Analysis was performed according to the manufacturer\'s instructions.

Quantification of HDL proteins
------------------------------

Sample preparation and quantification of HDL proteins were performed as described previously [@B19]. Briefly, apolipoprotein B (apoB)-depleted serum was prepared from thawed serum samples by precipitation of apoB-containing lipoprotein fractions with 20 % polyethyleneglycol (Sigma-Aldrich, USA) in 200 mM glycine buffer, pH 7.4, diluted at 1:2.5. After incubation for 20 min, samples were centrifuged at 16.000xg for 30 min. The supernatant (apoB-depleted serum) was collected and stored at -80°C until further use. HDL-bound SAA and SPB were measured according to a self-developed ELISA protocol [@B19]. Binding of HDL directly from apoB-depleted serum samples onto ELISA plates was accomplished using a coating antibody against HDL (Sigma-Aldrich, USA) at 1µg/ml. HDL samples (10µg/ml) with defined high and low amounts of SAA and SPB were used as positive and negative controls on every plate. Serum samples were added in triplicates (diluted at 1:50) for 90 min, followed by 60 min incubation with primary antibodies against SAA and SPB (Santa Cruz Biotechnologies, USA) and respective secondary biotin-conjugated antibodies (Southern Biotech, USA) for further 60 min. After addition of streptavidin-peroxidase (Roche, Switzerland) to the plate for 30 min, protein levels were detected with tetramethylbenzidine substrate (Sigma-Aldrich, USA) and optical density was measured at 450 nm. Data is expressed as values normalized to the ratio of positive to negative control. The intra-assay CV for SAA and SPB were 6.2% and 4.7%, respectively. The interassay CV was 9.3% for SAA and 14.5% for SPB.

Statistical analysis
--------------------

Statistical analysis was accomplished using SPSS 20.0. Continuous and normally distributed data is described by mean ± standard deviation (SD). Non-normally distributed data is described by median/25^th^ quartile/75^th^ quartile. Single correlations involving only two normally distributed data were calculated using Pearson Correlation, single correlations involving two non-parametric data and/or ordinal data were calculated using Spearman\'s rho analysis. Backwards multiple linear regression analysis was performed to investigate the association of co-variables such as age, BMI, packyears, body fat and apolipoproteins with baseline SAA and SPB. To further investigate the correlation of baseline SPB with the smoking status we added a Bonferoni adjusted post hoc analysis.

As it was expected that not all of the subjects would reach an adequate performance gain during the observation period we defined in the forefront a minimum threshold of 8 % performance gain as significant and divided the study population into the 4 mentioned groups. To investigate the difference between baseline and 8 month levels we used a parametric test for 2 related samples (paired sample t-test). To investigate trends over the observation period of 8 months we used the Friedman test. All tests were performed in accordance with two-sided testing and *p* values ≤0.05 were considered significant.

Results
=======

The study population consisted of 38 female and 60 male subjects. Baseline anamnestic, anthropometric and laboratory parameters for the 4 groups are shown in ***Table [1](#T1){ref-type="table"}***. As mentioned in the material and methods section the classification of the groups is based on the baseline performance and the performance gain. Although dyslipidemia was very prevalent (29 of 98 participants; 29.6%), only 5 participants were under statin therapy.

Baseline parameters (sex, smoking status, weekly alcohol intake, apolipoproteins, Il-6, hsCRP) and SAA/SPB-levels
-----------------------------------------------------------------------------------------------------------------

At baseline, when analysing the entire cohort, female participants had significantly higher HDL-levels (68±20 vs. 53±13 mg/dl; p\<0.001) and SAA-levels compared to men (0.12±0.06 vs. 0.09±0.06; p=0.024) but there was no sex-specific difference in SPB-levels (0.13±0.07 vs. 0.14±0.09; p=0.658).

Individuals with a basic performance \>100 % (group 3+4) showed higher HDL-levels compared to initially non-sportive individuals from group 1+2 with a basic performance ≤99 % but without statistically significant difference (60.91±14.06 vs. 55.24±21.01 mg/dl; p=0.115). Concerning baseline SAA, SPB, ApoA1 and ApoB levels there was no statistically significant difference between group 3+4 and group 1+2 too.

***Figure [1](#F1){ref-type="fig"}*** shows SAA and SPB-levels dependent on the smoking status. Smokers showed only minimally higher levels of SAA compared to non- and never-smokers while SPB-levels were significantly higher in smokers (0.21±0.11) compared to ex-smokers (0.10±0.06 and 0.13±0.05) and never-smokers (0.11±0.05) (ANOVA F=12.7; p\<0.001).

We next determined clinical predictors for the HDL proteins SAA and SPB (***Table [2](#T2){ref-type="table"})***. Significant predictors for SPB-levels were smoking status, BMI and weekly alcohol consumption (F=9.4; p\<0.001), whereas age, sex, body fat, apolipoprotein, hsCRP and Il-6-levels were not significant.

Weekly alcohol consumption also significantly predicted SAA-levels together with sex and hsCRP-levels (F= 13.6 p\<0.001) whereas age, sex, body fat, apolipoprotein and Il-6-levels were not significant.

Influence of physical activity on HDL-cholesterol, apolipoproteins, SAA and SPB
-------------------------------------------------------------------------------

Levels of HDL-cholesterol, apolipoprotein (Apo) A1, ApoB, SAA and SPB at the different points of measurement are shown in ***Table [3](#T3){ref-type="table"}***. Concerning HDL-cholesterol, group 2 showed a significant increase from 52±13 to 57±16 mg/dl (≙ 9.6 %; p=0.004); the increase in group 1 (≙ 1.7 %; p=0.710), group 3 (≙ 6.6 %; p=0.064) and group 4 (≙ 3.3 %; p=0.370) was not significant.

Similar results were observed for ApoA1: group 2 showed a significant increase from 146±24 to 160±36 mg/dl (≙ 11.0 %; p=0.002), group 1 from 157±42 to 162±32 mg/dl (≙ 3.2 %; p=0.154), group 3 from 159±18 to 170±23 mg/dl (≙ 6.9 %; p=0.025) and group 4 from 157±22 to 164±24 mg/dl (≙ 4.5 %; p=0.040).

***Figure [2](#F2){ref-type="fig"}*** demonstrates the course of HDL-C, SAA and SPB during the study period according to the groups. HDL-C only increased significantly in group 2 which had low baseline HDL-levels compared to group 4. However, we found no considerable changes in SAA in group 2 and 3. Intriguingly, SAA levels in group 1 increased after 3 months, but declined to baseline values after 8 months, whereas group 2 displayed decreased SAA after the first 4 months of intervention. In contrary, SPB levels increased mildly after 4 months with no further increase at the end of the study period.

Concerning ApoB, SAA and SPB, paired sample t-test and Friedman test showed no significant change in any of the groups and no significant difference between the values at the beginning and the end of the study.

Discussion
==========

In addition to hypertension, smoking, adipositas/overweight, diabetes mellitus and physical inactivity, hyper- and/or dyslipidaemia have been recognized for decades to be one of the most important cardiovascular risk factors. The term dyslipidaemia covers a spectrum of numerous lipid abnormalities however, research and prevention are mostly focused on changes in plasma lipoprotein function and/or levels. Due to their strong relation to CVD and outcome total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL) and triglycerides (TG) have evolved as key players regarding the possibility of modification by lifestyle and/or drug therapy. Although several prospective studies suggested apolipoprotein B (ApoB), the major apolipoprotein of very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and LDL, to be equal to LDL-C in risk prediction [@B22], it constitutes only a minor part in CVD risk calculation similar to Apo A1, the major protein component of HDL.

Although we could show that long-term physical activity leads to a significant increase in HDL-quantity in previously non-sportive individuals, we did not observe an influence on SAA and SPB-levels reflecting HDL-quality. The role of dietary CVD-prevention has been extensively investigated and reviewed. Numerous studies showed a strong beneficial effect of reduction of saturated fat [@B23] and trans fat [@B24] on TC, LDL-C and HDL-C levels. Concerning sports similar effects were observed. It was shown that increased habitual physical activity leads to a significant increase in HDL [@B25] and PCSK9 levels [@B26] in addition to a decrease of TC and LDL-C [@B27] and also TG levels [@B25] underlining the protective effect of physical activity on the lipid profile and CVD risk. It was further shown that an energy expenditure of about 1500-2200 kcal/week (corresponding e.g. 25-30 km of brisk walking) may increase HDL levels by 3-6 mg/dl.

The vasoprotective effect of HDL is mostly mediated by its stimulating effect on endothelial nitric oxide-production, thereby reducing the production of endothelial reactive oxygen species (ROS). HDL carries several protein components which are crucial for its intrinsic functional properties such as the apolipoproteins ApoA1 and ApoB or paraoxonase-1 [@B28], [@B29]. Furthermore, HDL also presents a carrier of serum amyloid A (SAA), however, SAA is an acute-phase protein and able to replace Apo A1 and consequently to impair HDL-mediated anti-oxidative effects [@B30], reverse cholesterol transport [@B31] and anti-inflammatory properties [@B12]. For example, Dullaart et al. [@B32] could show that the anti-oxidative function of HDL is inversely correlated with circulating SAA levels in patients with metabolic syndrome. This indicates that higher SAA levels detain HDL in exerting its full anti-oxidative activity. In this regards, we found elevated SAA levels in the female participants and smokers in addition to a positive correlation of SAA with hsCRP, a marker of a permanently prevalent chronic inflammation. Females are known to have higher HDL-levels compared to men however, the association of female sex with higher SAA-levels in our study population might be a sign of impairment of the beneficial effect of HDL in women.

The association of smoking and SPB-levels was a further interesting finding. Increased levels of circulating SPB have been reported in smoke exposure due to alveolar inflammation and increased lung permeability [@B33]. In our study, smokers showed 91 % higher SPB levels compared to never-smokers and 62 % higher levels compared to ex-smokers indicating that smoking is associated with an impairment of the molecular composition of HDL. The authors of the "Dallas Heart Study" [@B17] even suggested SPB to be a useful marker of the dose-dependent vascular effects of smoking. It is well known that smoking has a damaging effect on the vascular endothelium however, we speculate that this impairing impact might partly be mediated by affecting HDL composition.

In addition, we observed an association between the weekly alcohol intake and both SAA and SPB. The influence of alcohol intake on the lipid profile has been discussed for centuries but to our knowledge, SAA and SPB have never been in the spotlight of this discussion. Light to moderate alcohol intake has been shown to ameliorate the quantitative lipid profile, in particular by increasing HDL and reducing LDL-levels, however, as mentioned above, not only HDL quantity but also HDL quality seems to be important for the beneficial effect of HDL on the cardiovascular outcome. We could demonstrate that the weekly alcohol intake was a significant predictor for both SAA and SPB levels. Schwartz et al. could show that adding dalcetrapib, a cholesterylester transfer protein inhibitor, to the standard therapy after an acute coronary syndrome raised HDL and apolipoprotein A1-levels but did not significantly alter the major cardiovascular outcome [@B34]. Voight et al. even speculate that lifestyle interventions and pharmacologic treatment raising plasma HDL levels cannot be assumed to lead to a corresponding benefit with respect to risk of myocardial infarction [@B35]. In this light, our results relativize the beneficial effect of alcohol intake on the lipids. Light and moderate alcohol consumption might increase HDL levels but this protective effect might be mitigated by impairing HDL-quality.

Conclusion
==========

Long-term physical activity increases ApoA1 levels up to 11 % and HDL-quantity up to 10 % but seems to have no influence on its composition reflected by SAA and SPB as markers of HDL-quality. Smoking is associated with higher SPB-levels and the weekly alcohol intake is associated with both higher SAA and SPB-levels suggesting a damaging effect of drinking alcohol on the HDL-quality. It seems reasonable to assume that HDL-quality is at least as important as HDL-quantity when investigating the role of HDL in (cardiovascular) disease. Therefore, HDl-quality should receive much more attention in further studies dealing with HDL.

Limitations
-----------

First, although the number of participants is relatively high for a prospective study investigating the role of long-term physical activity on specific laboratory parameters, there might have been uncontrolled influencing factors. Second, the assumptions dealing with the associations between sex/smoking status/alcohol intake/Il-6/hsCRP and SAA/SPB were assessed only at inclusion time and thus are non-prospective data. Third, due to the low number of female participants it was not possible to perform a sex-specific analysis.
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CABG

:   coronary artery bypass graft

CVD

:   cardiovascular disease

DBP

:   diastolic blood pressure

FT

:   Friedman test

HbA1~c~

:   hemoglobin A1c, glycated hemoglobin

HR

:   heart rate

K

:   potassium

MI

:   myocardial infarction

Na

:   sodium

NO

:   nitric oxygen

PCI

:   percutaneous coronary intervention

PCSK9

:   proprotein convertase subtilisin/kexin type 9

ROS

:   reactive oxygen species

SAA

:   serum amyloid A

SPB

:   surfactant protein B

SBP

:   systolic blood pressure

TC

:   total cholesterol

TG

:   triglycerides

![**SPB and SAA-levels dependent on the smoking status** Figure [1](#F1){ref-type="fig"} shows the SPB and SAA-levels dependent on the smoking status. SPB-levels were significantly higher in smokers (0.21±0.11) compared to ex-smokers (0.10±0.06 and 0.13±0.05) and never-smokers (0.11±0.05) while the difference in SAA-levels was minimal.](ijmsv14p1040g001){#F1}

![**Progression of HDL, SAA and SPB levels over 8 months** Figure [2](#F2){ref-type="fig"} shows the progression (measurement every 2 months) of HDL (mg/dl), SAA and SPB-levels over the observation period of 8 months in the 4 groups. Group 2 showed a significant increase in HDL-levels from 52±13 to 57±16 mg/dl. There was no significant change in SAA or SPB-levels in any of the groups.](ijmsv14p1040g002){#F2}

###### 

Baseline risk factor profile, anthropometric and routine laboratory parameters

                            Initially non-sportive (n=42)               Initially sportive (n=56)                           
  ------------------------- ------------------------------- ----------- --------------------------- ----------- ----------- ---------
  Hypertension              n=7/35%                         n=10/48%                                n=8/29%     n=7/24%     
  Dyslipidaemia             n=5/25%                         n=6/29%                                 n=12/43%    n=6/21%     
  Diabetes mellitus         n=2/10%                         n=0/0%                                  n=1/4%      n=1/3%      
  Overweight                n=15/75%                        n=13/62%                                n=18/64%    n=18/62%    
  Ex-Smoking                n=9/45%                         n=7/33%                                 n=16/57%    n=10/35%    
  Smoking                   n=7/35%                         n=6/29%                                 n=3/11%     n=4/14%     
  Known CHD/stroke          n=3/15%                         n=3/14%                                 n=2/7%      n=8/28%     
  Family anamnesis          n=10/50%                        n=10/48%                                n=13/46%    n=11/38%    
  Alcohol (units/week)      1.3±1.7                         3.4±3.6     0.030                       3.0±3.4     3.5±4.9     0.677
  Age (years)               49.2±7.3                        48.7±7.9    0.839                       49.6±6.9    49.5±5.6    0.907
  BMI (kg/m^2^)             28.4±4.2                        28.2±5.7    0.897                       26.9±3.8    27.0±3.0    0.958
  Body water (%)            48.6±3.5                        51.3±5.1    0.068                       53.4±6.2    54.7±6.1    0.405
  Body fat (%)              33.9±4.8                        30.4±6.9    0.066                       29.5±12.9   25.6±8.3    0.182
  Body muscle (%)           32.2±3.3                        34.8±4.1    0.030                       34.4±4.0    36.7±3.7    0.030
  SBP (mmHg)                140±15                          145±14      0.137                       140±16      144±13      0.580
  DBP (mmHg)                85±8                            85±8        0.685                       83±13       85±7        0.182
  Performance gain (%)      1.6±5.0                         15.8±6.0    \<0.001                     -0.6±5.9    14.5±4.3    \<0.001
  Erythrocytes (T/l)        4.7±0.4                         4.8±0.5     0.407                       4.5±0.4     4.8±0.4     0.004
  Haemoglobin (g/dl)        13.9±1.6                        14.1±1.5    0.635                       13.7±1.1    14.4±1.1    0.023
  Haematocrit (%)           39.8±4.0                        40.4±3.4    0.613                       39.6±2.9    41.1±2.9    0.062
  Thrombocytes (G/l)        248±67                          238±53      0.584                       255±55      244±38      0.408
  Leukocytes (G/l)          7.7±1.9                         6.2±1.4     0.005                       6.5±1.7     6.1±1.1     0.361
  Na (mmol/l)               141±2                           141±1       1.000                       141±2       142±2       0.215
  K (mmol/l)                4.1±0.3                         4.6±0.2     0.268                       4.3±0.2     4.2±0.3     0.534
  Cl (mmol/l)               101±2                           101±2       0.502                       101±2       101±2       0.928
  Ca (mmol/l)               2.3±0.1                         2.3±0.1     0.386                       2.3±0.1     2.3±0.1     0.432
  Phosphate (mmol/l)        1.1±0.2                         1.0±0.1     0.296                       1.1±0.2     1.1±0.1     0.346
  Mg (mmol/l)               0.83±0.05                       0.85±0.06   0.468                       0.83±0.07   0.85±0.05   0.311
  Creatinine (mg/dl)        0.83±0.17                       0.86±0.12   0.531                       0.92±0.18   0.94±0.16   0.517
  BUN (mg/dl)               17.3±18.8                       18.1±24.5   0.901                       14.0±3.8    14.2±3.8    0.846
  Uric acid (md/dl)         5.3±2.0                         5.2±1.2     0.892                       5.2±1.5     5.3±1.1     0.605
  Lipasis (U/l)             32.4±10.7                       38.4±15.3   0.150                       42.4±19.3   44.3±18.5   0.697
  Cholinesterasis (kU/l)    8.2±1.4                         8.5±1.8     0.491                       7.6±1.7     8.7±1.6     0.015
  Alcalic Phosphat. (U/l)   64±18                           73±73       0.580                       56±15       60±14       0.335
  GOT (U/l)                 26±8                            23±9        0.300                       26±6        25±6        0.472
  GPT (U/l)                 27±14                           30±16       0.589                       27±9        24±9        0.377
  Gamma-GT (U/l)            22±14                           46±85       0.215                       22±13       27±19       0.198
  LDH (U/l)                 179±30                          172±24      0.395                       174±26      170±22      0.580

Baseline risk factor profile, anthropometric and routine laboratory parameters of the 4 groups. CHD: coronary heart disease; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; BUN: blood urea nitrogen; GOT: glutamat-oxalacetat-transaminasis; GPT: glutamat-pyruvat-transaminasis;

###### 

Backwards multiple linear regression analysis

  SPB                 Regression coefficient B^b^   Standard error   β        T        significance
  ------------------- ----------------------------- ---------------- -------- -------- --------------
  (Constant)          0.189                         0.051                     3.702    \<0.001
  Smoking             0.041                         0.010            0.393    4.222    \<0.001
  BMI                 -0.003                        0.002            -0.180   -1.925   0.057
  Alcohol cons.       0.004                         0.002            0.179    1.904    0.060
  F=9.4; p\<0.001                                                                      
  **SAA**                                                                              
  (Constant)          0.123                         0.019                     6.499    \<0.001
  Sex                 -0.026                        0.011            -0.209   -2.298   0.024
  hsCRP               0.143                         0.026            0.493    5.555    \<0.001
  Alcohol cons.       -0.003                        0.001            -0.173   -1.889   0.062
  F= 13.6; p\<0.001                                                                    

Table [2](#T2){ref-type="table"} shows the results of the backwards multiple linear regression analysis for SPB and SAA. Sex, BMI, age, body fat, apolipoprotein A1, apolipoprotein B, weekly alcohol consumption, hsCRP and Il-6 were inserted as independent variables.

###### 

Influence of physical activity on the lipid profile

                   Initially non-sportive (n=42)               Initially sportive (n=56)               
  ---------------- ------------------------------- ----------- --------------------------- ----------- -----------
  HDL baseline     59±27                           52±13                                   61±12       61±16
  HDL 2 months     59±28                           55±15                                   67±15       63±18
  HDL4 months      64±28                           54±17                                   65±12       64±17
  HDL 6 months     63±24                           53±14                                   66±14       61±15
  HDL 8 months     60±23                           57±16                                   65±14       63±18
  p-value          0.710                           0.004                                   0.064       0.370
  SAA baseline     0.11±0.05                       0.11±0.07                               0.10±0.07   0.08±0.05
  SAA 4 months     0.12±0.07                       0.10±0.06                               0.10±0.06   0.08±0.06
  SAA 8 months     0.11±0.06                       0.10±0.06                               0.10±0.06   0.08±0.05
  p-value          0.769                           0.484                                   0.839       0.297
  SPB baseline     0.15±0.08                       0.13±0.09                               0.14±0.06   0.13±0.08
  SPB 4 months     0.16±0.08                       0.13±0.08                               0.15±0.07   0.14±0.08
  SPB 8months      0.16±0.08                       0.12±0.07                               0.15±0.07   0.14±0.08
  p-value          0.454                           0.209                                   0.588       0.173
  ApoA1 baseline   157±42                          146±24                                  159±18      157±22
  ApoA1 2 months   161±41                          155±31                                  171±23      164±28
  ApoA1 4 months   165±37                          161±40                                  170±19      164±28
  ApoA1 6 months   170±37                          155±36                                  171±24      161±23
  ApoA1 8 months   162±32                          160±36                                  170±23      164±24
  p-value          0.156                           0.002                                   0.025       0.040
  ApoB baseline    103±29                          110±22                                  96±19       102±29
  ApoB 2 months    111±36                          108±25                                  104±26      102±24
  ApoB 4 months    102±31                          109±18                                  103±21      99±26
  ApoB 6 months    106±39                          104±23                                  100±21      95±24
  ApoB 8 months    104±32                          103±24                                  97±19       97±24
  p-value          0.910                           0.101                                   0.674       0.096

Table [3](#T3){ref-type="table"} shows HDL, SAA, SPB, ApoA1 and ApoB levels at the different points of measurement and p-values of the significance between the first and last point of measurement. HDL: high-density lipoprotein; SAA: serum amyloid A; SPB: surfactant protein B; Apo: apolipoprotein
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